Key Takeaways
- CDMO-led growth with injectables coming online: Generic Formulations CDMO drove revenue, while the injectable facility earned WHO GMP licenses and commercialized its first products in Q4, though management declined to share any ramp-up timeline.
- Minimum wage spike absorbed: A ~25% Uttarakhand minimum wage increase hit costs, but operating leverage and non-injectable margin strength offset the impact, keeping overall EBITDA growth healthy.
- Trade generics ambition is explicit: Management stated Windlas should aspire to reach the INR2,000-plus crore scale of Cipla and Alkem, from a base it describes as 1/10th that size, with a plan to expand stockist coverage from ~1,000 to 5,000-6,000.
- Plant 6 on track for FY26: The acquired oral solids facility is being retrofitted and should be ready within FY26; depreciation of INR8.3 crores per quarter is sustainable until then.
- What to watch next quarter: Whether injectable commercialization accelerates beyond the few products shipped in Q4, any update on Plant 6 capex magnitude, and progress on the trade generics stockist expansion.
Injectable Facility: The Big Bet, Still Unscored
- Status: The injectable and lyophilized vial lines completed stability batches, media fill, and WHO GMP licensing in FY25. Several large customers have approved the facility, and a few products were commercialized by both CDMO and Trade Generics verticals in Q4.
- Ramp-up opacity: Management declined to share any timeline for reaching 50-60% capacity utilization, break-even at EBITDA or PBT level, or peak utilization, calling it competitively sensitive. Internal targets exist but are not disclosed.
- Sales mix intent: Initially, the CDMO vs trade generics split from injectables should roughly mirror the overall business at 70-75% CDMO. Longer term, the company wants to prioritize exports from this facility for stronger margin opportunities.
- Asset-turn math: Injectable asset turns of 1.1-1.2x are structurally lower than oral solids at ~3x, because injectables carry higher gross margins but also higher fixed costs from 24x7 air handling and microbial control that cannot be shut down. Peak utilization could be slightly above oral at ~75%, but depends heavily on product mix and changeover frequency.
- ROCE promise: Once injectable sales shift toward exports and margins improve, ROCE should be similar to or better than oral plants.
Hitesh Windlass: "We are looking to ramp up. And obviously, our goal is to achieve that in the fastest possible way. And so we are on the job and expecting to build this business strongly in the future. Exactly how and when and what will be -- we'll be able to achieve, that is something that we are not discussing, although obviously, we have internal targets for everything."
Trade Generics: Scaling Ambition, Distributed Model
- The aspiration: Management explicitly benchmarked against Cipla and Alkem at INR2,000-plus crores, arguing there is no structural reason Windlas cannot reach that scale given its manufacturing capability and product understanding. Current size is roughly 1/10th of those peers.
- Distribution build-out: The model is designed ground-up for a distributed market. The plan is to expand from ~1,000 stockists to 5,000-6,000 to achieve all-India coverage, using a manpower-light model with geography-specific staffing decisions.
- Demand tailwind: Management pointed to hospital bed growth in non-metro areas as evidence that healthcare consumption is reaching populations previously unserved, creating a structural demand driver for trade generics.
Hitesh Windlass: "From our perspective, we really look at trade generics as a very strong space. And there is no reason why Windlas should also not aspire to reach the levels at which Cipla and Alkem are today. They are at INR2,000-plus crores. So why shouldn't a good manufacturer like us who has the opportunities, who understands the products and is able to build sustainably."
CDMO & Exports: The Core Engine
- Generic Formulations CDMO benefited from new customer additions and a broader product portfolio, remaining the primary growth driver.
- Exports optimism: The company remains very optimistic about the target market and continues to file dossiers to build the base for upcoming periods.
- Volume-led growth: Since the business is cost-plus and conversion costs remain typical, most growth is volume-linked. Management declined to share specific volume growth figures for the quarter or full year.
- MedPlus relationship: MedPlus is already a CMO customer, receiving white-label products manufactured by Windlas.
Margins & Costs: Wage Hit, Leverage Offset
- Minimum wage impact: Uttarakhand implemented a ~25% minimum wage increase, described by management as "very massive," which flowed through costs.
- Operating leverage working: Despite the wage increase, the company delivered strong EBITDA growth even as a percentage of revenue outside the injectables business. Injectables opex and additional depreciation from Injectables and Plant 2 extension are the drag; stripping those out shows strong underlying P&L performance.
- Cost outlook: Increments on the existing employee base will increase costs going forward. When Plant 6 is capitalized, basic manpower will be added but no huge bump like FY24 to FY25. Minimum wage is likely to see no increase this year.
- Margin expansion timing: Management expects margin expansion ultimately but declined to specify when.
Balance Sheet & Capital Allocation
- Working capital discipline: A 14-day working capital cycle is attributed to financial discipline maintained top to bottom, with everyone conscious of how decisions impact working capital and liquidity.
- Plant 6 acquisition: The recently acquired oral solids facility is being modernized and retrofitted as per plan. Commercialization is expected within FY26, and capex for Plant 6 will occur during FY26. Depreciation of INR8.3 crores per quarter is sustainable until Plant 6 gets capitalized.
- M&A appetite: The company wants to expand dosage form-wise and is exploring M&A for synergistic fits. Sufficient cash and debt capacity exist with no size restriction. If no suitable M&A target is found, organic capex will follow after the injectables business is stabilized and no longer consumes disproportionate management bandwidth.
- Dividend: A dividend of INR12.1 crores (INR5.8 per share) was proposed for FY25. The policy is to continue paying ~20% of profits as dividends unless there is reason for an exception.
- CFO vacancy: The CFO position was opened and offer letters issued but did not work out. Given a strong balance sheet and solid accounts/finance team, filling the role is not a top priority currently; management may reconsider if bandwidth becomes an issue.
Komal Gupta: "If we get an opportunity which fits in properly, synergistic fit, we would go ahead and do that. As you also mentioned, we have sufficient cash in place and debt taking capability is also there. So there is no restriction in terms of size."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Plant 6 commercialization | Oral solids facility ready and operational | Within FY26 |
| Plant 6 capex | Capex spending on Plant 6 retrofit | During FY26 |
| Depreciation level | INR8.3 crores per quarter sustainable | Until Plant 6 is capitalized |
| Dividend policy | Continue paying ~20% of profits | Ongoing, barring exceptions |
| Trade generics stockist expansion | Expand from ~1,000 to 5,000-6,000 stockists | No timeline given |
| Injectable sales mix shift to exports | Prioritize exports for stronger margins | Longer term |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹202.7 cr, +18.3% YoY, ninth straight quarter of record revenue |
| FY25 Revenue | ₹759 cr, +20.4% YoY |
| EBITDA | ₹25.5 cr, +16% YoY |
| FY25 EBITDA | ₹94.1 cr, +20% YoY |
| PAT | ₹16.3 cr, vs ₹17 cr in Q4 FY24 |
| FY25 PAT | ₹61 cr, vs ₹58.2 cr in FY24 |
| EPS (FY25) | ₹29.19, highest ever post listing |
| Generic Formulations CDMO revenue | ₹147.2 cr, +15% YoY |
| Trade Generics & Institutional revenue | ₹45.5 cr, +31% YoY |
| Exports revenue | ₹10 cr, +12% YoY |
| Working capital days | 14 days |
| ROCE and ROE | greater than 20%, sustained alongside capacity expansion |
| Liquidity | ₹213 cr |
| Oral solids capacity utilization | 60% to 62% in FY25 |
| Depreciation | ₹8.3 cr for the quarter, includes Plant 2 extension and injectables |
| Injectable revenue | ~₹6 cr, largely from Q4 FY25 |
| Trade generics chronic vs acute mix | 60% chronic and sub-chronic, 40% acute |